Tests surgery for cervical cancer that remains after chemoradiation
Tests surgery in adults with cervical cancer still present after chemoradiation.
Plain-language title generated from the registry record
Registry title: The Efficacy of Salvage Surgery in Patients With Residual Tumor After Concurrent Chemoradiation for Locally Advanced Cervical Cancer.
Key facts
- Where
- Chongqing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with locally advanced cervical cancer who still have cancer left after chemoradiation and can have salvage surgery.
- Age
- 18 to 70 years
- Sex
- Women only
- Disease stage
- Cervical cancer FIGO 2018 stage Ib3 and IIA2-IVA (squamous cell carcinoma, adenosquamous cell carcinoma or adenocarcinoma), with residual disease after treatment
- Earlier treatment
- Must have finished standard concurrent chemoradiation (pelvic EBRT, platinum-containing chemotherapy and brachytherapy). Residual cancer is confirmed 4-12 weeks after treatment by biopsy or PET/CT.
- Biomarker or test result
- If the cervical biopsy is negative, PET/CT must show SUVmax of 2.5 or higher in the residual lesions in the cervix and/or pelvic lymph nodes.
Main reasons for not taking part
- Radiotherapy or chemotherapy not completed, or radiotherapy dose not reached
- Distant spread, including para-aortic lymph nodes
- Another cancer diagnosed within five years or needing treatment
- History of important organ transplantation
- Kidney, liver, lung or heart conditions that rule out surgery
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT05749887, who can take part
Where in China
- Chongqing Cancer HospitalChongqing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Chongqing University Cancer Hospital
- Trial code
- NCT05749887
- Record updated
- 10 October 2023
- Original description
This is a single-center single-arm study. The main purpose of this study is to study the efficacy of surgical treatment for patients with locally advanced cervical cancer (FIGO IB3, IIA2-IVA) who still have residual tumor after concurrent radiotherapy and chemotherapy.Read full original descriptionShow less
Salvage Surgery for Patients With Residual Disease After Concurrent Chemoradiation Therapy for Locally Advanced Cervical Cancer: A Prospective, Single-arm Clinical Study.
This is a single-center single-arm study. The main purpose of this study is to study the efficacy of surgical treatment for patients with locally advanced cervical cancer (FIGO IB3, IIA2-IVA) who still have residual tumor after concurrent radiotherapy and chemotherapy.
Inclusion: Stage Ib3 and IIA2-IVA (FIGO2018) cervical cancer with histopathology of squamous cell carcinoma, adenosquamous cell carcinoma, adenocarcinoma; Complete standard CCRT(Pelvic EBRT+ concurrent platinum-containing chemotherapy+ brachytherapy); After 4-12 weeks of treatment, the cervical biopsy pathology confirmed residual cancer, or the cervical biopsy was negative, but PET /CT showed that SUVmax of the residual lesions in the cervical and/or pelvic lymph nodes were ≥ 2.5, two or more gynaecological oncologists with Grade IV operation qualification and the title of deputy director or above have gynecological examination, and the multidisciplinary team(MDT) evaluation recommended surgical treatment; ECOG score:0 ~ 1; The expected survival time>6 months; There is no absolute contraindication of surgery and the patients with good compliance.
Exclusion: The radiotherapy and chemotherapy are not completed or the radiotherapy dose is not reached; Drug abuse or drug use history; Those who are unable or unwilling to accept surgical treatment/sign informed consent/comply with research requirements; Other concomitant diseases or special conditions seriously endanger the patient's health or interfere with the trial; Other malignancies were diagnosed within five years or needed treatments; History of important organ transplantation; History of immune disease who need to take immunosuppressive drugs; History of serious mental illness and brain functional disorder; Without surgical conditions: 1) Chronic renal insufficiency or renal failure; 2) Liver insufficiency; 3)Chronic lung disease with restrictive respiratory dysfunction; 4) Cardiac dysfunction (patients with relative and absolute contraindications to surgery after consultation by cardiac physicians; PET /CT and/or pathological indicates that there is a distant metastasis including para-aortic lymph nodes; Participants in other clinical trials at the same time; Patients who cannot understand the research regimen and refuse to sign the informed consent form.